Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Emergent BioSolutions (EBS) will host a conference call on November 2, 2026, to discuss its third-quarter 2026 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Participants can access the conference call via webcast and also by visiting the Investors page of Emergent’s website. Participants can pre-register for the teleconference at the following link and will receive an email with a calendar reminder, dial-in number and a unique code that allows immediate access to the call.
To join by telephone on November 2:
-
North America Toll-Free: +1 833-461-5787
International Toll: +1 585-542-9983
International Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers
Meeting ID: 688 313 100
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261015164675/en/
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
Source: Emergent BioSolutions Inc.